Anna-laura Kretz

Albert Einstein Allee 23
Ulm, BW 89081, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer.

Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer.

Journal: Biomedicines

Published: December 01, 2022

The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death.

The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death.

Journal: Anticancer research

Published: September 13, 2021

Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers.

Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers.

Journal: Cell death and differentiation

Published: March 31, 2021

Friend or Foe: S100 Proteins in Cancer.

Friend or Foe: S100 Proteins in Cancer.

Journal: Cancers

Published: June 29, 2020

TRAILblazing Strategies for Cancer Treatment.

TRAILblazing Strategies for Cancer Treatment.

Journal: Cancers

Published: March 11, 2019

The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.

The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.

Journal: International journal of molecular sciences

Published: August 31, 2018

Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.

Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.

Journal: Cancers

Published: February 28, 2018

CDK9 is a prognostic marker and therapeutic target in pancreatic cancer.

CDK9 is a prognostic marker and therapeutic target in pancreatic cancer.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: February 25, 2017

CK1α overexpression correlates with poor survival in colorectal cancer.

CK1α overexpression correlates with poor survival in colorectal cancer.

Journal: BMC cancer

Published: August 23, 2016

Decreased CK1δ expression predicts prolonged survival in colorectal cancer patients.

Decreased CK1δ expression predicts prolonged survival in colorectal cancer patients.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: October 21, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026